2026年3月11日星期三,Zymeworks (NASDAQ:ZYME)在2026年Citizens生命科学大会上发表演讲,概述了其稳健的财务状况以及以创新和增长为核心的战略愿景。讨论重点介绍了其主打药物zanidatamab的巨大潜力,以及其雄心勃勃的扩张计划所涉及的战略风险。

04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和 ...

Investing.com - Stifel周一将 Zymeworks Inc. (NASDAQ:ZYME) 的目标价从40美元上调至47美元,同时维持对该股的买入评级。该股目前交易价格为24.05美元,较新目标价有95%的上涨潜力,过去一年已实现83%的回报。 该公司表示,仅基于合作伙伴Jazz Pharmaceuticals和Oncorus ...

The price trend for Zymeworks Inc. (ZYME) has been bearish lately and the stock has lost 7.6% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

With customers interested in getting more out of their data, the channel data management (CDM) company Zyme is bolstering its partnership with data visualization company Qlik. We delve into where IoT ...

Zymeworks Inc. (ZYME) shares rallied 5.3% in the last trading session to close at $8.90. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Zymeworks Inc. (ZYME) closed the last trading session at $18.62, gaining 17.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

A Series of Forbes Profiles of Thought Leaders Changing the Business Landscape: Chandran Sankaran, Founder, Zyme. There is $5 trillion being sold through indirect channels of resellers, integrators ...